241 filings
Page 8 of 13
UPLOAD
kiikil
19 Apr 19
Letter from SEC
12:00am
8-K
9zt6iidu 91ykc3
25 Feb 19
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
8:16am
8-K
bugzz31g hyzk
25 Feb 19
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
8:15am
CT ORDER
uhj0 8yw3d
30 Nov 18
Confidential treatment order
11:08am
424B5
3w8izh1 5g6
9 Nov 18
Prospectus supplement for primary offering
12:00am
8-K
uzev2
9 Nov 18
Other Events
12:00am
8-K
o6yn3 o2i00yhbn
7 Nov 18
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
5:22pm
8-K
xav2ya209p3
10 Oct 18
Regulation FD Disclosure
5:25pm
424B5
azwojy7bp5z9xm8l
24 Sep 18
Prospectus supplement for primary offering
8:23pm
8-K
j2g5559a0qvxtz
24 Sep 18
Entry into a Material Definitive Agreement
5:27pm
8-K
8hf g5gqsb
21 Sep 18
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:16pm
424B5
xl7u9c vr3fircz3j
21 Sep 18
Prospectus supplement for primary offering
4:10pm
424B5
fxgutqqai96
19 Sep 18
Prospectus supplement for primary offering
4:21pm
S-3ASR
40ludoo o7y
19 Sep 18
Automatic shelf registration
4:02pm
8-K
0wkj7w7 8yh
17 Sep 18
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
12:00am
8-K
i3kxpfsuyzmy
11 Sep 18
Other Events
12:00am
424B5
7lypcomcj dz
31 Aug 18
Prospectus supplement for primary offering
12:00am